-
-
-
-
-
-
-
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
-
-
-
-
-
-
-
AMGEN announces $300 million US manufacturing investment
-
-
-
-
-
-
-
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
-
-
-
-
-
-
-
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
-
-
-
-
-
-
-
FDA grants full approval for Amgen's IMDELLTRA in lung cancer
-
-
-
-
-
-
-
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
-
-
-
-
-
-
-
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
-
1,175,278 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

